Loading
Life sciences · Journal article
Allergologia Et Immunopathologia · November 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the treatment of type 2 diabetes mellitus (T2DM) and obesity due to their glycemic and metabolic benefits. Although hypersensitivity reactions have been described, anaphylaxis to oral semaglutide remains rare.3 To date, no standardized desensitization protocol for oral semaglutide has been established. Case report: A 60-year-old woman developed immediate anaphylaxis within minutes of ingesting oral semaglutide (3 mg/day). Symptoms included generalized urticaria, facial angioedema, laryngospasm, and dyspnea, requiring intramuscular epinephrine. Serum tryptase was not obtained due to resource limitations. Skin testing was performed using concentrations previously reported as nonirritating. Intradermal testing was positive at 1:10 dilution, supporting an IgE-mediated mechanism. Due to significant metabolic benefit and lack of effective alternatives, a rapid 13-step oral desensitization protocol was performed with premedication. The patient has remained asymptomatic under continuous daily therapy since September 2025. Conclusions: Rapid oral desensitization may allow safe continuation of semaglutide in selected patients with confirmed immediate hypersensitivity when no suitable alternatives exist.